Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenfa Huang

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Frontiers in Immunology|August 5, 2025
Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expressionXiaomin Zhang, Lixin Wang, Jingqiao Qiao, et al.
Blood Cancer Journal|August 7, 2024
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trialLixin Wang, Chuling Fang, Qingzheng Kang, et al.
Journal of Translational Medicine|November 11, 2025
Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myelomaChuling Fang, Lixin Wang, Weiqiang Zhao, et al.
Journal for Immunotherapy of Cancer|May 17, 2026
Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphomaLixin Wang, Chuling Fang, Yuanyuan Zheng, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Frontiers in Immunology|August 5, 2025
Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expressionXiaomin Zhang, Lixin Wang, Jingqiao Qiao, et al.
Blood Cancer Journal|August 7, 2024
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trialLixin Wang, Chuling Fang, Qingzheng Kang, et al.
Journal of Translational Medicine|November 11, 2025
Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myelomaChuling Fang, Lixin Wang, Weiqiang Zhao, et al.
Journal for Immunotherapy of Cancer|May 17, 2026
Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphomaLixin Wang, Chuling Fang, Yuanyuan Zheng, et al.
Pageof 2